DisclosureWe earn commission on partner links; ranking is set by our published methodology — not advertisers.
semaglutide (Ozempic) and injection-site reactions: incidence, timing, mechanism, evidence-graded management, and when to escalate.
Cells graded on a calm severity scale (lighter = lower). Figures are from each drug's pivotal trial / FDA label and are not head-to-head; doses and populations differ.
Typical onset, peak, and resolution from pivotal-trial timing. Drag the slider to read what most patients experience that week. Individual experience varies — this is a guide, not medical advice.
Within hours to a day or two of an injection. Usually mild and self-limited over a few days; rotating sites prevents recurrence.
Local response to the subcutaneous injection of Ozempic — redness, itching, a small lump, or bruising at the site. Daily injectables (liraglutide) tend to report these more often than weekly ones.
Rotate injection sites (abdomen, thigh, upper arm) and avoid the exact same spot.
Standard injection technique; reduces local reactions and lipohypertrophy.
Let the pen reach room temperature and inject slowly to reduce sting.
Comfort measure; widely advised, limited formal evidence.
A cool compress eases redness or itching after injecting.
Symptomatic; low-risk.
Do not reuse needles.
Sterility/safety standard for all injectables.
Each step is graded A (strongest evidence) to D (weakest), on the same scale used across LoseLab. Grades reflect strength of supporting evidence, not how essential a step is for you.
Injection-site reactions are a technique problem far more than a drug problem. Rotation and a room-temperature pen resolve the large majority.
| Symptom | Incidence | Onset |
|---|---|---|
| Nausea | 20% | Usually 24–48 h after the first dose and after each dose step-up. |
| Vomiting | 9% | Clusters in the first week of each new dose step, often after overeating past the new appetite ceiling. |
| Diarrhea | 9% | Most common in the first 4 weeks of each titration step; often alternates with constipation. |
| Constipation | 5% | Builds gradually over the first 4–8 weeks. |
| Fatigue | 5% | Most common in the first month of titration and during periods of very low intake. |
| Headache | 7% | Variable; clusters around titration and dehydration episodes (after nausea or diarrhea). |
| Sulfur burps | Less common | Can appear within days of a dose, often after high-protein, high-sulfur, or fatty meals. |
| Injection-site reaction | 4% | Within hours to a day or two of an injection. |
| Facial fat loss ("Ozempic face") | Common | Becomes visible after roughly 8–12% total body-weight loss, typically months 3–6. |
| Muscle / lean-mass loss | Common | Begins with weight loss itself (weeks–months); proportion of lean loss is highest when loss is fast and protein/training are low. |
| Hair loss (telogen effluvium) | 3% | Typically 2–4 months after the period of fastest weight loss (delayed, by design of the hair cycle). |
Editorial summary, not medical advice. Incidence figures from FDA prescribing information and pivotal trial publications; qualitative bands are used where no trial reports a clean percentage. Individual experience varies. Coordinate side effect management with your prescriber.